Source-grounded facts extracted from RAPID MICRO BIOSYSTEMS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
RAPID MICRO BIOSYSTEMS, INC. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-05-21 meeting.
“The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
RAPID MICRO BIOSYSTEMS, INC. shareholders approved Election of Richard Kollender as Class II Director at the 2026-05-21 meeting.
“The Company’s stockholders elected Richard Kollender as a Class II Director to serve until the 2029 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until such director’s earlier death, resignation or removal.”
RAPID MICRO BIOSYSTEMS, INC. reported full year 2026 results: revenue full year 2026 total revenue guidance range of $37.0 million to $41.0 million. Guidance reaffirmed.
“Reaffirms full year 2026 total revenue guidance range of $37.0 million to $41.0 million including a range of 30 to 38 Growth Direct system placements”
RAPID MICRO BIOSYSTEMS, INC. reported first quarter ended March 31, 2026 results: revenue Total revenue for the first quarter of 2026 increased 11.1% to $8.0 million compared to $7.2 million in the first quarte, net income Net loss for the first quarter of 2026 was $14.3 million, EPS net loss per share was $0.31.
“Total revenue for the first quarter of 2026 increased 11.1% to $8.0 million compared to $7.2 million in the first quarter of 2025.”
RAPID MICRO BIOSYSTEMS, INC. reported full year 2026 results: revenue $37.0 million to $41.0 million. Guidance initiated.
“For the full year 2026, the Company expects total revenue in the range of $37.0 million to $41.0 million including a range of 30 to 38 Growth Direct system placements and gross margins of approximately 20%.”
RAPID MICRO BIOSYSTEMS, INC. reported full year 2025 results: revenue $33.6 million, net income $47.1 million, EPS $1.05.
“Total revenue for the full year was $33.6 million in 2025, compared to $28.1 million in 2024, representing an increase of 20%.”
RAPID MICRO BIOSYSTEMS, INC. reported fourth quarter of 2025 results: revenue $11.3 million, net income $12.5 million, EPS $0.28.
“Total revenue for the fourth quarter of 2025 was $11.3 million, compared to $8.2 million in the fourth quarter of 2024, representing an increase of 37%.”
RAPID MICRO BIOSYSTEMS, INC. incurred term loan of $20.0 million with Trinity Capital Inc. at the greater of (a) the sum of (i) The Wall Street Journal Prime Rate and (ii) 4. maturing September 1, 2030.
“On August 8, 2025 (the "Closing Date"), Rapid Micro Biosystems, Inc. (the "Company") entered into a Loan and Security Agreement (the "LSA") with the lenders party thereto (the "Lenders") and Trinity Capital Inc., as administrative agent and collateral agent (the "Agent"). Under the LSA, the Lenders agreed to extend debt capital to the Company, in the form of a term loan, in tranches totaling an aggregate principal amount of up to $45.0 million available as follows: (a) at closing, an aggregate principal amount of $20.0 million (the "First Tranche")”
Jeffrey Schwartz resigned as Director at RAPID MICRO BIOSYSTEMS, INC..
“On May 22, 2025, Jeffrey Schwartz notified Rapid Micro Biosystems, Inc. (the "Company") of his resignation from the board of directors of the Company and all committees thereof, effective as of May 22, 2025.”
David Hirsch resigned as director at RAPID MICRO BIOSYSTEMS, INC..
“On October 29, 2024, David Hirsch, M.D., Ph.D., notified the Company of his resignation from the board of directors of the Company and all committees thereof, effective as of November 1, 2024.”
RAPID MICRO BIOSYSTEMS, INC. reported first quarter ended March 31, 2024 results: revenue $5.6 million, net income $13.3 million, EPS $0.31. Guidance reaffirmed.
“Rapid Micro Biosystems Reports First Quarter 2024 Financial Results Reports first quarter 2024 total revenue of $5.6 million”
RAPID MICRO BIOSYSTEMS, INC. updated its fourth quarter and fiscal year ended December 31, 2023 guidance (initiated).
“On March 1, 2024, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fourth quarter and fiscal year ended December 31, 2023.”
RAPID MICRO BIOSYSTEMS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“stock”) had closed below $1.00 per share for the thirty (30) consecutive business days (December 18, 2023 through February 1, 2024) and that the Company therefore is not in compliance with the minimum bid price requirement for continued inclusion on the Nasdaq Stock Market under Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The notification has no immediate effect on the listing of the Company’s common stock on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days to regain compliance with the Bid Price Requirement, which wi”
RAPID MICRO BIOSYSTEMS, INC. reported preliminary financial results for fourth quarter and full year ended December 31, 2023.
“On January 10, 2024, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenue results and certain business highlights for the fourth quarter and full year ended December 31, 2023.”
RAPID MICRO BIOSYSTEMS, INC. reported third quarter ended September 30, 2023 results: revenue $6.1 million, net income $13.4 million, EPS $0.31. Guidance reaffirmed.
“Total revenue for the third quarter of 2023 increased 30% to $6.1 million”
RAPID MICRO BIOSYSTEMS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“) had closed below $1.00 per share for the thirty (30) consecutive business days (July 31, 2023 through September 11, 2023) and that the Company therefore is not in compliance with the minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The notification has no immediate effect on the listing of the Company’s common stock on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days to regain compliance with the Bid Price Requirement, which wi”
RAPID MICRO BIOSYSTEMS, INC. reported the second quarter ended June 30, 2023 results: revenue $5.0 million. Guidance reaffirmed.
“expressly stated in such filing. --- EX-99.1 (EX-99.1) --- Rapid Micro Biosystems Reports Second Quarter 2023 Financial Results Reports second quarter 2023 total revenue of $5.0 million, representing growth of 30% compared to second quarter 2022 Reaffirms full year 2023 total revenue guidance of at least $22.0 million, representing growth of approximately 30%”
Jeffrey Schwartz resigned as Chair of the Board at RAPID MICRO BIOSYSTEMS, INC..
“Jeffrey Schwartz resigned as Chair of the Board as of the Effective Date and will continue to serve as a member of the Board.”
Kirk D. Malloy was appointed as Chair of the Board at RAPID MICRO BIOSYSTEMS, INC..
“appointed Kirk D. Malloy, Ph.D. to serve as a Class III member of the Board and Chair of the Board, effective as of July 14, 2023 (the “Effective Date”).”
RAPID MICRO BIOSYSTEMS, INC. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-04 meeting.
“2. The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the stockholders’ vote with respect to such ratification were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 34,810,913 24,946 619 0”
RAPID MICRO BIOSYSTEMS, INC. shareholders approved Election of Class II Directors to serve until the 2026 Annual Meeting at the 2023-05-04 meeting.
“1. The Company’s stockholders elected Jeffrey Schwartz, Richard Kollender and Natale Ricciardi as Class II Directors to serve until the 2026 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified or until such director’s earlier death, resignation or removal. The results of the stockholders’ vote with respect to the election of such Class II Directors were as follows: Votes For Votes Withheld Broker Non-Votes Jeffrey Schwartz 26,007,817 1,756,781 7,071,880 Richard Kollender 23,893,108 3,871,490 7,071,880 Natale Ricciardi 25,721,530 2,043,068 7,071,880”
RAPID MICRO BIOSYSTEMS, INC. reported first quarter ended March 31, 2023 results: revenue $5.0 million, net income $13.9 million, EPS $0.32. Guidance reaffirmed.
“expressly stated in such filing. --- EX-99.1 (EX-99.1) --- Rapid Micro Biosystems Reports First Quarter 2023 Financial Results Reports first quarter 2023 total revenue of $5.0 million, representing growth of 21%, compared to first quarter 2022 Reaffirms full year 2023 total revenue guidance of at least $22.0 million, representing growth of approximately 30%,”
RAPID MICRO BIOSYSTEMS, INC. reported full year 2023 results: revenue at least $22.0 million. Guidance initiated.
“For the full year 2023, the Company expects commercial revenue of at least $22.0 million, including the placement of at least 15 new systems.”
RAPID MICRO BIOSYSTEMS, INC. reported the fiscal year ended December 31, 2022 results: revenue $17.1 million, net income $60.8 million, EPS $1.43.
“Total revenue for the full year was $17.1 million in 2022, compared to $23.2 million in 2021.”
RAPID MICRO BIOSYSTEMS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $4.4 million, net income $16.4 million, EPS $0.39.
“Total revenue for the fourth quarter of 2022 was $4.4 million, compared to $5.2 million in the fourth quarter of 2021.”
RAPID MICRO BIOSYSTEMS, INC. reported preliminary financial results for fourth quarter and fiscal year ended December 31, 2022.
“On January 11, 2023, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenue results for its fourth quarter and fiscal year ended December 31, 2022.”
Richard Keys resigned as Chief Commercial Officer at RAPID MICRO BIOSYSTEMS, INC..
“Mr. Keys’ last date of employment with the Company as its Chief Commercial Officer was August 11, 2022”
Alexander Schmitz departed as Director at RAPID MICRO BIOSYSTEMS, INC..
“On March 23, 2022, Alexander Schmitz, a member of the Board of Directors (the “Board”) of Rapid Micro Biosystems, Inc. (the “Company”) informed the Company that he does not intend to stand for reelection at the Company’s 2022 annual meeting of stockholders (the “Annual Meeting”).”
Inese Lowenstein was appointed as Class III Director at RAPID MICRO BIOSYSTEMS, INC..
“On December 17, 2021, the Board of Directors (the “Board”) of Rapid Micro Biosystems, Inc. (the “Company”) appointed Inese Lowenstein to the Board.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.